𝔖 Bobbio Scriptorium
✦   LIBER   ✦

868 EFFICACY OF EZETIMIBE FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, CONTROLLED TRIAL

✍ Scribed by Y. Takeshita; T. Takamura; Y. Kita; H. Misu; K. Arai; T. Yamashita; E. Mizukoshi; S. Kaneko

Book ID
117380012
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
54 KB
Volume
54
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Betaine for nonalcoholic fatty liver dis
Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial
✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 227 KB πŸ‘ 2 views

Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified facto

Correction: Betaine for nonalcoholic fat
Correction: Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial
✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 46 KB πŸ‘ 2 views

Data describing cirrhosis prevalence in the simple steatosis group reported in the study by Rafiq et al. should read NR (not reported) instead of 42 (56.8%). All cirrhosis prevalence proportions were calculated based upon these correct (NR) data.